drugset / Trial / NCT02418247

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

NCT02418247 ↗

Phase 2/3 Unknown 556 enrolled National Cancer Center, Korea
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.

Timeline

Start
2013-05
Primary completion
2017-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator I123 Diagnostic / imaging agent 74 mbq —
Comparator I123 Diagnostic / imaging agent 222 mbq —
Comparator I131 Other / unclassified 1110 mbq —

Indications